All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
64 results for "Eye/Orbital Cancers"
Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced / Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
This clinical trial tests an investigational drug, STP705, that has shown through laboratory experiments to silence TGF-1 and COX-2 gene expressions, enzyme proteins believed to speed cancer growth in some cancers, which may result in tumor shrinkage when administered.
Protocol No
SIRNAOMICS-SRN-705-005
Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR ) versus Observation
Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer (AMBASSADOR)
Protocol No
ALLIANCE-A031501-AMBASSAD
Sub Category
Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Testing the addition of bevacizumab to AZD9291 (osimertinib) as a first-treatment for patients with EGFR-mutant lung cancer that has metastasized
Protocol No
ECOG-EA5182
Sub Category
Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis
Improving the Treatment of Immunotherapy-related Lung Inflammation in Patients where Corticosteroids are No Longer Effective
Protocol No
ECOG-EAQ172
Sub Category
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients, NCCAPS Study. How does COVID19 affect the outcomes of people undergoing cancer treatment? How does having cancer affect COVID-19?
Protocol No
NCI-COVID-NCCAPS
Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Protocol No
IIT-MCGONIGLE-ONA-NEUROPATHY
Sub Category
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma
JNJ-64407564 [anti-GPRC5DxCD3] is called a bispecific antibody because it has two arms that target a protein on the myeloma cells, GPRC5D, and a protein on T-cells, CD3. T-cells are a type of cell that can kill cancer cells. JNJ-64407564 [anti-GPRC5DxCD3] brings these killer T-cells to the myeloma cell resulting in myeloma cell death.
JNJ-64007957 [anti-BCMAxCD3] is called a bispecific antibody because it has two arms that target a protein on the myeloma cells, BCMA, and a protein on T-cells, CD3. T-cells are a type of cell that can kill cancer cells. JNJ-64007957 [anti-BCMAxCD3] brings ...
Protocol No
JANSSEN-64407564MMY1002
A Multisite Phase IB Study of Pevonedistat, Azacitidine (or Decitabine) and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)
The study hypothesis is that the combination of pevonedistat, azacitidine, and venetoclax will be effective, safe, and well tolerated in patients with AML.
Protocol No
IIT-ATALLAH-PAVE-AML
A Multicenter, Open-Label, Dose-Escalation Phase 1b Study Of AEVI-007 In Subjects With Relapsed Or Refractory Multiple Myeloma
AEVI-007,in the treatment of relapsed or refractory multiple myeloma.
Protocol No
AEVI-007-MM-101
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated,NS-NSCLC
Protocol No
CALITHERA-CX-839-014-KEAPSAKE
Sub Category
An Open-Label, Phase 1 Study Of KHK2455 In Combination With Avelumab In Adult Subjects With Locally Advanced Or Metastatic Urothelial Carcinoma
The main purposes of this study are to:
1. Test and study the side effects (to determine the safety) of KHK2455 when taken in combination with avelumab; and
2. Identify the highest dose of KHK2455 that can be given and safely tolerated in combination with avelumab.
1. Test and study the side effects (to determine the safety) of KHK2455 when taken in combination with avelumab; and
2. Identify the highest dose of KHK2455 that can be given and safely tolerated in combination with avelumab.
Protocol No
KYOWA-2455-002
A Phase 1, Open-Label Study In Two Parts, Evaluating The Safety, Tolerability, Pharmacokinetics, And Clinical Activity Of CCW702 In Patients With Metastatic, Castration Resistant Prostate Adenocarcinoma
The purpose of the study is to assess the safety, tolerability, the time course of the drug in your body known as pharmacokinetics, and the observed effects produced by the drug called pharmacodynamics of CCW702 (study drug) when given as an injection under your skin (subcutaneous injection) every other day for two weeks for a total of 6 doses in a twenty-eight (28) day cycle of dosing in patients like yourself who have been diagnosed with metastatic castration-resistant prostate cancer (mCRPC).
Protocol No
CALIBR-CBR-CCW702-3001
Sub Category
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Testing the effects of MK-3475 (pembrolizumab) with or without the usual chemotherapy treatment for patients 70 years of age and older with advanced non-small cell lung cancer
Protocol No
ALLIANCE-A171901
Sub Category
Phase 1/1b Study To Evaluate The Safety And Activity Of TTX-030 (Anti-CD39) In Combination With Budigalimab And/Or Chemotherapy In Subjects With Advanced Solid Tumors
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Protocol No
TRISHULA-TTX-030-002
A Phase Ib/II Study of the Microenvironment Modifier L-DOS47 Plus Doxorubicin for the Treatment of Patients with Previously Treated Advanced Pancreatic Cancer
The purpose of this study is to evaluate in patients with metastatic pancreatic cancer, the overall safety, tolerability, and preliminary anti-tumor activity of adding an investigational drug, L DOS47, to doxorubicin, a type of chemotherapy drug
Protocol No
HELIX-LDOS006
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide in mCRPC
Protocol No
MERCK-MK-3475-641
Sub Category
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Protocol No
ALLIANCE-A031102
Sub Category
A Phase I, Open-Label, Multicenter, Study of WVT078 in Subjects with Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to find the best dose of WVT078 or WVT078 combined with WHG626 that can be given to patients with multiple myeloma and to evaluate how well the treatment might work in treating patients with this type of cancer. This is the first time WVT078 or WVT078 combined with WHG626 are being used in humans. WHG626 has been studied previously in patients with different types of cancer than yours
Protocol No
NOVARTIS-CWVT078A12101
Sub Category
Phase 1/2 FIH Study of REGN5459 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma
The main purpose of this study is to learn about the safety of REGN5459 and to find out what is the best dose of REGN5459 to give to patients with multiple myeloma. An additional purpose is to look for any signs that REGN5459 can treat your cancer.
Protocol No
REGENERON-R5459-ONC-1888
Sub Category
A Phase 1b Trial of Magrolimab Monotherapy Or Magrolimab In Combination With Azacitidine In Patients With Hematological Malignancies
The purpose of this study is to test the safety of Hu5F9-G4 alone, or in combination with azacitidine in patients with blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Other purposes of this study are to determine the best dose of Hu5F9-G4, the quantity of Hu5F9-G4 in your blood, the side effects it has on your body, and whether or not it can improve your cancer.
Protocol No
FORTYSEVEN-5F9005
Sub Category
A Phase I/Ib Open-label, Multi-center Dose Escalation Study of JBH492 in Patients with Relapsed/refractory Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
The purpose of this clinical research study is to identify an appropriate safe dose of JBH492 that can be given to patients with NHL or CLL who did not improve after treatment with currently available therapies, have had their disease worsen, and/or cannot tolerate currently available therapies. This study will also evaluate how well JBH492 might work in treating your disease and will give us an understanding how your body responds to the study treatment. In order to achieve this, a number of blood and tissue samples will be collected during the study.
Protocol No
NOVARTIS-CJBH492A12101
Sub Category